These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 20002080)

  • 81. Is Obesity the New Hypertension? Parallels in the Evolution of Obesity and Hypertension as Recognized Disease States.
    Umashanker D; Shukla AP; Saunders KH; Aronne LJ
    Curr Atheroscler Rep; 2017 Aug; 19(8):35. PubMed ID: 28660593
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Long-term pharmacotherapy for obesity and overweight.
    Padwal R; Li SK; Lau DC
    Cochrane Database Syst Rev; 2003; (4):CD004094. PubMed ID: 14584004
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Weight matters. How new antiobesity drugs can be part of diabetes management.
    Tsai A
    Diabetes Forecast; 2015; 68(1):50-5. PubMed ID: 25647938
    [No Abstract]   [Full Text] [Related]  

  • 84. Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice.
    Gadde KM; Pritham Raj Y
    Curr Diab Rep; 2017 May; 17(5):34. PubMed ID: 28378293
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Pharmacotherapy considerations in diabetes and obesity: setting patients up for success.
    Cornell S; D'Souza J
    Postgrad Med; 2014 Mar; 126(2):100-9. PubMed ID: 24685973
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Treatment of obese diabetics.
    Svacina S
    Adv Exp Med Biol; 2012; 771():459-64. PubMed ID: 23393696
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Therapeutic options for modifying cardiometabolic risk factors.
    Aronne LJ
    Am J Med; 2007 Mar; 120(3 Suppl 1):S26-34. PubMed ID: 17320519
    [TBL] [Abstract][Full Text] [Related]  

  • 88. An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity.
    Christopoulou FD; Kiortsis DN
    J Clin Pharm Ther; 2011 Feb; 36(1):10-8. PubMed ID: 21198716
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Obesity and insulin resistance: Pathophysiology and treatment.
    Tong Y; Xu S; Huang L; Chen C
    Drug Discov Today; 2022 Mar; 27(3):822-830. PubMed ID: 34767960
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Therapy of obese patients with cardiovascular disease.
    Jindal A; Whaley-Connell A; Brietzke S; Sowers JR
    Curr Opin Pharmacol; 2013 Apr; 13(2):200-4. PubMed ID: 23332347
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Safety of antiobesity drugs.
    Cheung BM; Cheung TT; Samaranayake NR
    Ther Adv Drug Saf; 2013 Aug; 4(4):171-81. PubMed ID: 25114779
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Low adoption of weight loss medications: A comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s.
    Thomas CE; Mauer EA; Shukla AP; Rathi S; Aronne LJ
    Obesity (Silver Spring); 2016 Sep; 24(9):1955-61. PubMed ID: 27569120
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Cardiovascular co-medication among users of antiobesity drugs: a population-based study.
    Amundsen MO; Engdahl B; Berg C; Nordeng H
    Pharm World Sci; 2010 Dec; 32(6):752-8. PubMed ID: 20803315
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Pharmacotherapy of obesity in complex diseases.
    Pulipati VP; Pannain S
    Clin Obes; 2022 Feb; 12(1):e12497. PubMed ID: 34889046
    [TBL] [Abstract][Full Text] [Related]  

  • 95. New agents in development for the management of obesity.
    Vincent RP; le Roux CW
    Int J Clin Pract; 2007 Dec; 61(12):2103-12. PubMed ID: 17850307
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Antiobesity drug therapy: An individualized and comprehensive approach.
    Mauer Y; Parker M; Kashyap SR
    Cleve Clin J Med; 2021 Aug; 88(8):440-448. PubMed ID: 34341028
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Pharmacotherapy in Childhood Obesity.
    Kühnen P; Biebermann H; Wiegand S
    Horm Res Paediatr; 2022; 95(2):177-192. PubMed ID: 34351307
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Flavonoids as antiobesity agents: A review.
    Rufino AT; Costa VM; Carvalho F; Fernandes E
    Med Res Rev; 2021 Jan; 41(1):556-585. PubMed ID: 33084093
    [TBL] [Abstract][Full Text] [Related]  

  • 99. FDA approval of obesity drugs: a difference in risk-benefit perceptions.
    Morrato EH; Allison DB
    JAMA; 2012 Sep; 308(11):1097-8. PubMed ID: 22990266
    [No Abstract]   [Full Text] [Related]  

  • 100. Models and strategies in the development of antiobesity drugs.
    Agahi A; Murphy KG
    Vet Pathol; 2014 May; 51(3):695-706. PubMed ID: 23860008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.